A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain | MicrobiomeTrials← Back to trialsNCT07598448
A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-09-10Est. Completion: 2026-12-15
Enrollment target: 35 participants ContactNovartis Pharmaceuticals
Other microbiome trials you might be interested in
IgA Nephropathy (IgAN)C3 GlomerulopathyIC-MPGN
This study looks at how well and safely SGB-9768 works for patients with certain kidney diseases: primary IgA nephropath…
Beijing, ChinaEst. completion Dec 29, 2026
Immunoglobulin A Nephropathy (IgAN)Complement 3 Glomerulopathy (C3G)IC-MPGN
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults …
Shenzhen, ChinaEst. completion Jul 10, 2028